U.S-Australia Cancer Moonshot Initiative
U.S. Embassy & Consulates in Australia; February 3, 2024
The U.S. Ambassador to Australia announced a significant new initiative to highlight the work being done in both the United States and Australia to advance research, share best practices, and improve the lives of people with cancer, survivors, and their families.
The U.S.-Australia Moonshot Initiative was launched on World Cancer Day, Sunday, February 4. Ambassador to Australia Caroline Kennedy said “We know that no one country can end the fight against
“This initiative will highlight the work being done in both the United States and Australia to advance research, share best practices, and improve the lives of people with cancer, survivors, and their families.”
Read the full announcement on the U.S. Embassy & Consulates in Australia website
Multi-Stakeholder Private-Public Alliance Mobilizes Biden-Albanese Talks to Transform Cancer Care
Bloomberg New Economy, January 30th 2024
Following President Biden and Prime Minister Albanese’s announcement of U.S.-Australia cooperation in innovative technologies, a U.S.-Australia Cancer Consortium was formed, focusing on pioneering cancer care collaboration.
Cure4Cancer And Partners To Convene International Experts To Advance The Global Fight Against Cancer
Forbes China, September 2023
Forbes China announced its fourth Forbes China Healthcare Summit will take place virtually on Sept. 22, 2023 in the U.S. (Sept. 23, 2023 in China). The theme of this year’s summit will be “Advancing Global Health Equity To Cure Cancer”.
Dr. Bob Li joins Centerpoint to Discuss New Breakthroughs in the Area of Precision Medicine and the Cure4Cancer International Movement
The Honorable Dr. Kevin Rudd AC: Joint Fight Against Cancer Can Help Re-Energize U.S.-China Ties
U.S., China Advance Discussions on Pact To Accelerate Cancer Drug Trials
加入我们
聚爱愈癌（Cure4Cancer，C4C）是一项国际合作计划及倡议，它将患者、临床医生、科学家、政策制定者、监管者、工业界、慈善事业、媒体以及其他密切相关的利益相关者聚集在一起，共同致力于全球抗癌事业。我们欢迎各方人加入，在我们的有生之年加速实现“聚爱愈癌（Cure4Cancer）”。
加入我们，聚爱愈癌
#聚爱愈癌
与我们分享你的故事
或者了解关于我们的使命的更多内容
新闻中的Cure4Cancer
中美就加速癌症药物试验的协议展开讨论
Russell Flannery, Forbes.com, 17 December 2022
Health experts from the United States and China recently engaged in discussions regarding a potential collaboration to accelerate the fight against cancer by participating in multi-regional clinical trials. Following a summit between U.S. President Joe Biden and China President Xi Jinping in Indonesia, potential areas of improvement in the strained relationship between the two countries were identified, with a focus on cancer research and treatment. Jingquan Bi, a key figure in China’s health and drug regulatory sector, expressed optimism about overcoming obstacles related to a confidentiality agreement to allow China’s participation in Project Orbis, an initiative aimed at expediting cancer drug approvals through simultaneous regulatory reviews.
Project Orbis, led by the U.S. FDA Oncology Center of Excellence, involves several countries collaborating to review clinical trial data concurrently, thus reducing the time required for cancer patients to access new drugs and treatments. While eight countries are currently part of Project Orbis, China is not included. Dr. Richard Pazdur, the head of
U.S. FDA’s Oncology Center, highlighted the necessity for pharmaceutical companies to make simultaneous submissions to expedite approvals where significant delays exist. The success of Project Orbis has been evident in facilitating communication among regulatory agencies and establishing uniform standards globally.
Efforts to involve China in Project Orbis may involve addressing complexities in confidentiality agreements and exploring new initiatives such as “Project Pragmatica” aimed at simplifying clinical trials. The collaboration in cancer research between the U.S. and China is seen as a pivotal opportunity to revitalize their relationship, particularly in the context of addressing the significant cancer burden in both countries. Prominent figures such as Kevin Rudd emphasized the importance of successful collaboration in cancer research as a means to inject positive momentum into U.S.-China relations, with potential benefits extending beyond healthcare to broader bilateral dynamics.
